AddexBio

Executive Summary

AddexBio is a private, pre-clinical biotechnology company headquartered in San Diego, California, founded in 2018. The company focuses on developing novel small molecule therapies targeting cancer metabolism, a promising area aimed at exploiting metabolic vulnerabilities in tumor cells. In parallel, AddexBio operates a comprehensive contract research organization (CRO) platform that provides drug discovery and development services to external clients. This dual business model allows the company to generate near-term revenue through its CRO services while advancing its internal pipeline toward the clinic. AddexBio's metabolic oncology programs are in the pre-clinical stage, with no disclosed compounds or targets yet. The company's approach emphasizes integration of its internal research capabilities with external client work, potentially enabling cross-fertilization of insights and technologies. As a private entity, financial details such as total funding and valuation are not publicly available, and the company does not have a listed ticker. The absence of disclosed pipeline details and limited public information suggest an early stage of development, with key milestones likely including lead optimization, IND-enabling studies, and initial clinical trial applications. AddexBio's location in San Diego's biotech hub provides access to talent and partnerships, but the competitive landscape in cancer metabolism and CRO services requires clear differentiation to succeed.

Upcoming Catalysts (preview)

• Q4 2026Lead Candidate IND Submission30% success
• Q2 2026CRO Service Partnership Announcement60% success
• Q3 2026Preclinical Data at Major Oncology Conference50% success